10-Q: TransCode Therapeutics Q3: Acquisition, Funding, Clinical Progress

TransCode Therapeutics reports a significant Q3 with a strategic acquisition, a $25 million investment, and advancement in its lead clinical programs, despite increased net losses.

Summary

• Acquired ABCJ, LLC (parent of Polynoma, LLC), adding the Phase 3-ready immuno-oncology vaccine seviprotimut-L for melanoma, effective October 8, 2025.
• Secured approximately $25 million in new equity financing from DEFJ, LLC concurrent with the acquisition, comprising $20 million cash and a $5 million promissory note due January 1, 2026.
• Amended the exclusive patent license agreement with Massachusetts General Hospital (MGH) on August 15, 2025, revising diligence requirements and milestone payments, including a $75,000 amendment fee.
• Completed enrollment for the Phase 1a clinical trial of lead candidate TTX-MC138, with analysis ongoing; 77 doses administered to 16 patients with advanced solid tumors, showing positive pharmacodynamic effects and good tolerability.
• Expects to commence a Phase 2a clinical trial for TTX-MC138 in the first half of 2026.
• Net loss for the nine months ended September 30, 2025, increased to $21.2 million from $10.8 million in the prior year.
• Cash position at September 30, 2025, was $2.8 million, projected to fund operations into the fourth quarter of 2026 with the new $25 million investment.
• Research and development expenses increased by $1.934 million for the three months and $1.879 million for the nine months ended September 30, 2025, primarily due to clinical trial spending and drug production.
• General and administrative expenses increased by $462 thousand for the three months but decreased by $493 thousand for the nine months ended September 30, 2025.
• Identified substantial doubt about the ability to continue as a going concern without additional capital.
• Appointed Philippe Calais as CEO and Elizabeth Czerepak to the Board, effective October 8, 2025.

Sentiment

Score: 5

Explanation: The company reported increased losses and a going concern warning, which are significant negatives. However, the strategic acquisition of a Phase 3-ready asset and a substantial capital raise are strong positive developments. Clinical trial progress for TTX-MC138 is also encouraging. The overall sentiment is neutral to slightly negative, reflecting a balance between high financial risk and promising pipeline advancements.

Positives

• Strategic acquisition of ABCJ, LLC (Polynoma), adding a Phase 3-ready immuno-oncology asset (seviprotimut-L) for melanoma.
• Secured $25 million in new equity financing, extending the cash runway into the fourth quarter of 2026.
• Successful completion of enrollment for the Phase 1a clinical trial of TTX-MC138, with preliminary data indicating no significant safety or dose-limiting toxicities.
• Positive pharmacodynamic effects observed in 16 patients treated with TTX-MC138, consistent with preclinical results.
• Planned commencement of the Phase 2a clinical trial for TTX-MC138 in the first half of 2026.
• Nasdaq listing compliance maintained as of June 2, 2025.
• Amendment to the MD Anderson collaboration agreement relieves the company from up to $10 million in collaboration payments.

Negatives

• Significant increase in net loss for the nine months ended September 30, 2025, to $21.2 million from $10.8 million in 2024.
• Accumulated deficit reached approximately $84.4 million as of September 30, 2025.
• Recurring and expected continuing losses from operations, leading to substantial doubt about the ability to continue as a going concern without additional capital.
• Cash balance of $2.8 million at September 30, 2025, indicating a strong reliance on recent and future capital raises.
• Increased R&D expenses due to clinical trial activities and drug production.
• Change in fair value of warrant liabilities resulted in a $9.676 million expense for the nine months ended September 30, 2025.

Risks

• Inability to raise additional capital on acceptable terms or at all, potentially leading to scaling back or terminating operations.
• Potential delisting from the Nasdaq Capital Market, which would reduce liquidity, adversely affect stock value, and make capital raising more difficult.
• Risk of total loss of investment for common stockholders and other securities holders in the event of future restructuring activities.
• Adverse global conditions, including economic uncertainty, tariffs, geopolitical instability (e.g., Ukraine, Middle East), and supply chain weaknesses, could negatively affect financial results.
• Changes in U.S. tax law (e.g., Section 174 of the IRC regarding R&D expense capitalization) may adversely affect cash flow.
• Inadequate funding for FDA, SEC, and other government agencies could hinder their ability to perform normal business functions, delaying product review/approval.
• Uncertainty regarding new initiatives, laws, regulations, policies, and guidance affecting product candidates or business operations.
• Inability to adequately protect information systems from cyberattacks, potentially leading to disclosure of confidential information, reputational damage, and financial/legal exposure.
• Reliance on third parties for preclinical studies, manufacturing, and clinical trials.
• Uncertainty of successful development and commercialization of product candidates, including regulatory approvals and market acceptance.
• Need to establish appropriate safety and efficacy profiles in IND-enabling studies.
• Costs and timing of manufacturing commercial-grade product and building inventory.
• Obtaining, maintaining, defending, and enforcing intellectual property rights.
• Maintaining an acceptable safety profile of product candidates following approval.

Future Outlook

The company expects to commence a Phase 2a clinical trial for TTX-MC138 in the first half of 2026. Management believes that current cash, combined with the October 2025 investment, will fund operating expenses and capital requirements into the fourth quarter of 2026. Beyond this period, additional capital will be required to support planned operations, which the company intends to raise through equity or debt sales, and government or other grants. Expenses and capital requirements are anticipated to increase substantially with ongoing preclinical and clinical development activities.

Management Comments

• We intend to work on developing both TTX-MC138 and seviprotimut-L, with the initial focus on advancing TTX-MC138 in a planned Phase 2a clinical trial.
• We believe there is potential to augment seviprotimut-L's focus with TTX-MC138 by addressing micrometastases in stage IIB and IIC melanoma patients.
• Preliminary data indicate no significant safety or dose limiting toxicities reported in the trial. To date, 77 doses of TTX-MC138 have been administered to 16 patients with advanced solid tumors. The median treatment duration of treatment is four months. Importantly, the duration of treatment for all patients ranged from two to twelve cycles indicative of tolerability and disease control. Sixteen patients showed positive pharmacodynamic effects over a wide dose range, consistent with preclinical results and TransCode’s Phase 0 clinical trial.
• Management believes that its cash at September 30, 2025, along with the net proceeds from the October 2025 Investment, is sufficient to fund operations and capital requirements into the fourth quarter 2026.

Industry Context

The company operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically targeting immuno-oncology and targeted cancer therapy through RNA-based therapeutics. The acquisition of Polynoma and its Phase 3-ready melanoma vaccine (seviprotimut-L) diversifies the company's pipeline beyond its core RNA platform (TTX-MC138), positioning it in a more advanced clinical stage for a specific cancer indication. The company's focus on RNA-based therapeutics aims to overcome historical delivery challenges in oncology, leveraging its TTX platform. The use of PET-MRI microdosing for drug delivery assessment represents an advanced technique in drug development, potentially offering advantages in early clinical phases.

Comparison to Industry Standards

• Nanoparticles similar in formulation to ours have an excellent clinical safety record of low toxicity and immunogenicity.
• Seviprotimut-L has been safely administered in clinical trials in more than 1,000 patients, indicating a strong safety profile for a Phase 3-ready vaccine.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings, and not aware of any pending or threatened legal proceedings that could have a material adverse effect on business, operating results, or financial condition, except for claims by an investment bank that it is entitled to fees, which the company rigorously disputes.

Related Party Transactions

• The acquisition of ABCJ, LLC and the concurrent $25 million investment were conducted with DEFJ, LLC, which became a significant shareholder.
• The Contingent Value Rights Agreement, Registration Rights Agreement, and Repurchase Agreement were also entered into with DEFJ, LLC.
• Tungsten Advisors (through Finalis Securities LLC) acted as financial advisor for the acquisition and placement agent for the investment, receiving 59.2255 shares of Series A Preferred Stock and $1,800,000 cash as compensation.

Stakeholder Impact

• Shareholders face potential for significant dilution from future capital raises and a risk of total loss of investment if restructuring occurs. Existing common stockholders as of October 20, 2025, received Contingent Value Rights (CVRs) entitling them to a share of future upfront and milestone payments.
• Employees: Headcount was reduced to seven employees at September 30, 2025, due to restructuring. A new CEO was appointed, and the CFO's salary was adjusted with bonuses.
• Creditors face a risk of restructuring if additional capital is not secured.
• Patients may benefit from potential new therapeutic options with the advancement of TTX-MC138 and the addition of seviprotimut-L to the pipeline.

Next Steps

• Advance TTX-MC138 in a planned Phase 2a clinical trial (expected H1 2026).
• Work on developing both TTX-MC138 and seviprotimut-L.
• Hold a stockholders meeting to approve the conversion of Series A Preferred Stock and a change of control under Nasdaq Listing Rules.
• File a proxy statement on Schedule 14A with the SEC within 30 days following receipt of required financial statements.
• Prepare and file a resale registration statement with the SEC within 75 calendar days following the closing of the Acquisition and October 2025 Investment.
• Continue to raise additional capital through equity/debt sales and grants.
• Expand development of lead therapeutic candidate and other candidates.
• Explore strategic partnerships.
• Continue to improve internal control over financial reporting.

Key Dates

Recommendation

The company has made significant strategic moves with the acquisition of a Phase 3-ready asset and secured crucial funding, which are strong positives. Early clinical data for TTX-MC138 also appears promising. However, the substantial increase in net losses, the explicit 'going concern' warning, and the continuous need for further capital introduce considerable risk. The stock is highly speculative, and while there's upside potential from pipeline advancement, the financial instability warrants caution. A 'Hold' recommendation reflects the balance between these high-risk, high-reward factors, suggesting current investors monitor developments closely rather than adding significantly or exiting.

Keywords

Biopharmaceutical, Oncology, Cancer Therapy, RNA Therapeutics, Clinical Trials, Metastatic Cancer, Melanoma, Immuno-oncology, TTX-MC138, Seviprotimut-L, SEC Filing, 10-Q, Financial Report, Nasdaq, Capital Raise, Patent License, Corporate Governance, Risk Factors